Pascal Announces the Appointment of a New Director, Dr.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
152
Pascal Announces the Appointment of a New Director, Dr. Graeme I. Bell

VANCOUVER, B.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSX VENTURE:PAS), a biotechnology company that specializes in cancer drug discovery and development, today announced the appointment of Dr. Graeme I. Bell to its Board of Directors.

Dr. Bell received his BSc and MSc degrees from the University of Calgary and his PhD from the University of California, San Francisco. He is currently the Kovler Family Distinguished Service Professor in Medicine, and Human Genetics at the University of Chicago. Dr. Bell is a member of the National Academy of Medicine and the American Academy of Arts and Sciences. For his pioneering work on the genetics of diabetes, he was awarded the 2013 Banting Medal for Scientific Achievement Award, the highest scientific honor from the American Diabetes Association. This prize is awarded annually in memory of the Canadian medical scientist Sir Frederick Banting, Nobel laureate who was one of the key investigators that discovered insulin.

“Dr. Bell is an exceptional medical scientist, and we are very pleased to have him join our Board,” said Dr. Patrick Gray, CEO of Pascal. “In addition to his distinguished and decorated career in medicine, Dr. Bell’s work has been the focus of entrepreneurial biotech startups. His significant insights will be invaluable as we develop novel therapeutics for cancer and advance these through clinical development.”

Dr. Bell has been honored with numerous additional awards recognizing his seminal contributions to the understanding of diabetes and metabolic disease. He gained recognition early in his career for the cloning of the human insulin gene, a landmark achievement that paved the way for the production of recombinant insulin. Demonstrating his entrepreneurial spirit, he became a founding scientist at Chiron, a leading biotechnology company that was later acquired by Novartis.  He has also been a founder and advisor for other biotech startups.

This appointment is subject to the TSXV approval.

On Behalf of the Board of Directors Patrick W. Gray, President & CEO

Company Contact: Dr. Patrick Gray Tel: 1-206-650-6765

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 19

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 21

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 74

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading
NVE Revenue Pull-Forward Raises Hard Investor Questions

Updated Category News Views 50

A Quarter Can Look Great Until It Doesn’t NVE investors got a nasty lesson in revenue timing, the sort that makes even old hands check the fine print twice. On July 22, 2026, the company reported sequential revenue growth of 43% and net-income growth of 23%. The next trading day, shares vaulted $47.53, or 54%. Then came October, and the floor gave way: NVE reported that...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 31

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 49

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 101

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 217

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating Component Obsolescence: Key Trends and Insights

Updated Category News Views 170

Understanding Component Obsolescence in Today's Market In the rapidly evolving world of semiconductors and electronic components, tracking obsolescence has become crucial. Bill Bradford, President of Flip Electronics, sheds light on these trends that are shaping the industry as we move towards 2026. The market has seen a significant shift, primarily due to increasing...

Continue Reading
Exploring Class Action Claims Against iLearningEngines - AILE

Updated Category News Views 181

Understanding the Class Action Lawsuit Against iLearningEngines Faruqi & Faruqi, LLP, a prominent name in securities litigation, is taking steps to inform investors about a significant class action lawsuit related to iLearningEngines, Inc. The law firm, known for its commitment to protecting investors' rights, has set a deadline for potential lead plaintiffs in this case....

Continue Reading
Key Stock Movements: Sanmina and other Performers Soar

Updated Category News Views 440

Key Stock Movements on Tuesday U.S. stocks exhibited mixed performance with the Dow Jones index declining around 100 points. Despite the overall market volatility, several companies reported substantial improvements in their stock values on Tuesday. Sanmina Corporation Performance Sanmina Corporation (NASDAQ: SANM) saw an impressive rise in its stock during Tuesday's...

Continue Reading
Segal Trials' Innovations in Schizophrenia Treatment with LB-102

Updated Category News Views 303

Segal Trials Advances Schizophrenia Research with LB-102 Segal Trials is making significant strides in the field of schizophrenia research, focusing on the innovative treatment method involving LB-102. This investigational drug, which is a potential first-in-class benzamide antipsychotic, is being evaluated in a Phase 2 trial. The main goal of this study is to assess the...

Continue Reading
Innovative Vehicle Safety System Promises Improved Driver Focus

Updated Category News Views 237

Introduction to an Innovative Safety Solution In today's fast-paced world, driving distractions can have serious consequences. An inventive mind has created a new device called SAFE DRIVE, aimed at enhancing driver concentration and reducing the risks associated with smartphone usage while driving. Concept Behind SAFE DRIVE The SAFE DRIVE invention is designed with a...

Continue Reading